{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:01:19Z","timestamp":1788415279553,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["200517\/Z\/16\/Z"],"award-info":[{"award-number":["200517\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CiC19017"],"award-info":[{"award-number":["CiC19017"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S00016X\/1"],"award-info":[{"award-number":["MR\/S00016X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201706250035"],"award-info":[{"award-number":["201706250035"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.apsb.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T02:48:54Z","timestamp":1600138134000},"page":"1835-1845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Neutralising effects of small molecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake venoms"],"prefix":"10.1016","volume":"10","author":[{"given":"Chunfang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Slagboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-9217","authenticated-orcid":false,"given":"Laura-Oana","family":"Albulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govert W.","family":"Somsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek J.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8035-4719","authenticated-orcid":false,"given":"Nicholas R.","family":"Casewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-5612","authenticated-orcid":false,"given":"Jeroen","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.09.005_bib1","first-page":"1","article-title":"Snakebite envenoming","volume":"3","author":"Guti\u00e9rrez","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2020.09.005_bib2","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1371\/journal.pntd.0007059","article-title":"Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming","volume":"13","author":"Williams","year":"2019","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib3","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1371\/journal.pmed.0050218","article-title":"The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths","volume":"5","author":"Kasturiratne","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.apsb.2020.09.005_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40409-017-0127-6","article-title":"Snakebite envenomation turns again into a neglected tropical disease!","volume":"23","author":"Chippaux","year":"2017","journal-title":"J Venom Anim Toxins incl Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003220","article-title":"Current treatment for venom-induced consumption coagulopathy resulting from snakebite","volume":"8","author":"Maduwage","year":"2014","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.14591","article-title":"Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise","volume":"177","author":"Slagboom","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.apsb.2020.09.005_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s42003-018-0039-1","article-title":"The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms","volume":"1","author":"Ainsworth","year":"2018","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2020.09.005_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fevo.2019.00218","article-title":"Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis","volume":"7","author":"Cardoso","year":"2019","journal-title":"Front Ecol Evol"},{"key":"10.1016\/j.apsb.2020.09.005_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2020.05.006","article-title":"Causes and consequences of snake venom variation","volume":"41","author":"Casewell","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2020.09.005_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/bcp.12739","article-title":"Adverse reactions to snake antivenom, and their prevention and treatment","volume":"81","author":"de Silva","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2020.09.005_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1590\/S1678-91992009000100002","article-title":"Snake antivenoms: adverse reactions and production technology","volume":"15","author":"Morais","year":"2009","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.toxicon.2013.01.002","article-title":"Antivenom therapy of carpet viper (Echis ocellatus) envenoming: effectiveness and strategies for delivery in West Africa","volume":"69","author":"Habib","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/molecules23020391","article-title":"Exploration of the inhibitory potential of varespladib for snakebite envenomation","volume":"23","author":"Wang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2020.09.005_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/toxins10120516","article-title":"Coagulotoxic cobras: clinical implications of strong anticoagulant actions of African spitting Naja venoms that are not neutralised by antivenom but are by LY315920 (varespladib)","volume":"10","author":"Bittenbinder","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.apsb.2020.09.005_bib15","doi-asserted-by":"crossref","first-page":"4320175","DOI":"10.1155\/2018\/4320175","article-title":"Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite","volume":"2018","author":"Bulfone","year":"2018","journal-title":"J Trop Med"},{"key":"10.1016\/j.apsb.2020.09.005_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8314","article-title":"Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite","volume":"12","author":"Albulescu","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.09.005_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/toxins12050309","article-title":"Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group I metalloprotease from the venom of the Western diamondback rattlesnake, Crotalus atrox","volume":"12","author":"Layfield","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.apsb.2020.09.005_bib18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.toxicon.2003.11.005","article-title":"Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity","volume":"42","author":"JMa","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.toxicon.2005.02.020","article-title":"Snake venom serine proteinases: sequence homology vs. substrate specificity, a paradox to be solved","volume":"45","author":"Serrano","year":"2005","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib20","series-title":"Handbook of natural toxin","first-page":"253","article-title":"Effect of snake venoms on factor V","author":"Kisiel","year":"2018"},{"key":"10.1016\/j.apsb.2020.09.005_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007041","article-title":"Mechanisms underpinning the permanent muscle damage induced by snake venom metalloprotease","volume":"13","author":"Williams","year":"2019","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/toxins8090248","article-title":"Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation","volume":"8","author":"Lewin","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.apsb.2020.09.005_bib23","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.CCM.0000053648.42884.89","article-title":"Efficacy and safety of LY315920Na\/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure","volume":"31","author":"Abraham","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.apsb.2020.09.005_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2018.11.292","article-title":"Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2","volume":"157","author":"Bryan-Quir\u00f3s","year":"2019","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib25","first-page":"639","article-title":"Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects","volume":"23","author":"King","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apsb.2020.09.005_bib26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.toxicon.2006.11.020","article-title":"Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators","volume":"49","author":"Howes","year":"2007","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1194\/jlr.M800361-JLR200","article-title":"The synergistic inhibition of atherogenesis in apoE\u2212\/\u2212 mice between pravastatin and\u00a0the sPLA2 inhibitor varespladib (A-002)","volume":"50","author":"Shaposhnik","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2020.09.005_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(09)60403-7","article-title":"Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial","volume":"373","author":"Rosenson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2020.09.005_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2020.09.005_bib30","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2174\/138161207782023784","article-title":"Trends in snakebite envenomation therapy: scientific, technological and public health considerations","volume":"13","author":"Gutierrez","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2020.09.005_bib31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C","article-title":"Matrix metalloproteinases in tumour invasion and metastasis","volume":"189","author":"Curran","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.apsb.2020.09.005_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0163-7258(97)00023-5","article-title":"Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat","volume":"75","author":"Rasmussen","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2020.09.005_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0162-0134(03)00100-4","article-title":"The interaction of metal ions and marimastat with matrix metalloproteinase 9","volume":"95","author":"Underwood","year":"2003","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.apsb.2020.09.005_bib34","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1073\/pnas.91.18.8447","article-title":"Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)","volume":"91","author":"Zhang","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.apsb.2020.09.005_bib35","doi-asserted-by":"crossref","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","article-title":"Matrix metalloproteinases","volume":"274","author":"Nagase","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2020.09.005_bib36","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1517\/13543784.9.12.2913","article-title":"Marimastat: the clinical development of a matrix metalloproteinase inhibitor","volume":"9","author":"Steward","year":"2000","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.apsb.2020.09.005_bib37","article-title":"A combination of two small molecule toxin inhibitors provides pancontinental preclinical efficacy against viper snakebite","author":"Albulescu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2020.09.005_bib38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbapap.2011.04.009","article-title":"Snake venom metalloproteinases: structure, function and relevance to the mammalian ADAM\/ADAMTS family proteins","volume":"1824","author":"Takeda","year":"2012","journal-title":"Biochim Biophys Acta Protein Proteonomics"},{"key":"10.1016\/j.apsb.2020.09.005_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13181-013-0347-2","article-title":"Current use of chelation in American health care","volume":"9","author":"Wax","year":"2013","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.apsb.2020.09.005_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40495-016-0068-8","article-title":"Chelators in iron and copper toxicity","volume":"2","author":"Lawson","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.apsb.2020.09.005_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.toxicon.2014.11.224","article-title":"Inhibitory potential of three zinc chelating agents against the proteolytic, hemorrhagic, and myotoxic activities of Echis carinatus venom","volume":"93","author":"Urs","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/156616a0","article-title":"British anti-lewisite (BAL)","volume":"156","author":"Peters","year":"1945","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.09.005_bib43","unstructured":"WHO model list of essential medicines, 20th list (March 2017, amended August 2017). Available from: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"key":"10.1016\/j.apsb.2020.09.005_bib44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s12098-010-0143-9","article-title":"Accidental inorganic mercury chloride poisoning in a 2-year old child","volume":"77","author":"Verma","year":"2010","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.apsb.2020.09.005_bib45","article-title":"Cardiac conduction block at multiple levels caused by arsenic trioxide therapy","volume":"29","author":"Kathirgamanathan","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.apsb.2020.09.005_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/MGC-180246","article-title":"Interaction of British anti-lewisite (BAL) with copper (I) and copper (II) compounds in conjunction with Wilson's disease","volume":"17","author":"Ioannou","year":"2018","journal-title":"Main Group Chem"},{"key":"10.1016\/j.apsb.2020.09.005_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/toxins9120382","article-title":"Multipurpose HTS coagulation analysis: assay development and assessment of coagulopathic snake venoms","volume":"9","author":"Still","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.apsb.2020.09.005_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007802","article-title":"High throughput screening and identification of coagulopathic snake venom proteins and peptides using nanofractionation and proteomics approaches","volume":"14","author":"Slagboom","year":"2020","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/toxins12010053","article-title":"Antivenom neutralization of coagulopathic snake venom toxins assessed by bioactivity profiling using nanofractionation analytics","volume":"12","author":"Xie","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.apsb.2020.09.005_bib50","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.toxicon.2009.07.001","article-title":"Epidemiological, clinical and therapeutic aspects of Bothrops asper bites","volume":"54","author":"Otero-Pati\u00f1o","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib51","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1371\/journal.pntd.0000318","article-title":"Effects of Bothrops asper snake venom on lymphatic vessels: insights into a hidden aspect of envenomation","volume":"2","author":"Mora Rodr\u00edguez","year":"2008","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002814","article-title":"Bothrops jararaca venom metalloproteinases are essential for coagulopathy and increase plasma tissue factor levels during envenomation","volume":"8","author":"Yamashita","year":"2014","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jprot.2016.07.006","article-title":"Venomics of Calloselasma rhodostoma, the Malayan pit viper: a complex toxin arsenal unraveled","volume":"148","author":"Tang","year":"2016","journal-title":"J Proteomics"},{"key":"10.1016\/j.apsb.2020.09.005_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.actatropica.2018.09.017","article-title":"Snake venom proteome and immuno-profiling of the hundred-pace viper, Deinagkistrodon acutus, in Taiwan","volume":"189","author":"Chen","year":"2019","journal-title":"Acta Trop"},{"key":"10.1016\/j.apsb.2020.09.005_bib55","first-page":"93","article-title":"Duration after Malayan pit viper bite to detect coagulopathy in Songklanagarind hospital","volume":"38","author":"Kraisawat","year":"2020","journal-title":"J Health Sci Med Res"},{"key":"10.1016\/j.apsb.2020.09.005_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40409-018-0179-2","article-title":"Clinical and laboratory features distinguishing between Deinagkistrodon acutus and Daboia siamensis envenomation","volume":"24","author":"Su","year":"2018","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"key":"10.1016\/j.apsb.2020.09.005_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cbi.2015.08.002","article-title":"Phospholipase A2 enhances the endothelial cell detachment effect of a snake venom metalloproteinase in the absence of catalysis","volume":"240","author":"Bustillo","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.apsb.2020.09.005_bib58","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.toxicon.2011.11.007","article-title":"Synergism between baltergin metalloproteinase and Ba SPII RP4 PLA2 from Bothrops alternatus venom on skeletal muscle (C2C12) cells","volume":"59","author":"Bustillo","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2020.09.005_bib59","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00018-008-8113-3","article-title":"Cellular pathology induced by snake venom phospholipase A2 myotoxins and neurotoxins: common aspects of their mechanisms of action","volume":"65","author":"Montecucco","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2020.09.005_bib60","first-page":"647","article-title":"Phospholipases A2 from viperidae snake venoms: how do they induce skeletal muscle damage?.","volume":"58","author":"Lomonte","year":"2011","journal-title":"Acta Chim Slov"},{"key":"10.1016\/j.apsb.2020.09.005_bib61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/toxins10110479","article-title":"Delayed LY333013 (oral) and LY315920 (intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of Micrurus fulvius (Eastern coral snake) venom","volume":"10","author":"Lewin","year":"2018","journal-title":"Toxins"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352030705X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352030705X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:46:30Z","timestamp":1761929190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138352030705X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S221138352030705X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.09.005","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralising effects of small molecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake venoms","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}